ArticleMedical oncology (Northwood, London, England)2026
Mechanism of Coumarin in the anti-liver cancer activity by promoting NK cell activation.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aims to elucidate the molecular mechanisms by which Coumarin exerts anti-liver cancer effects via natural killer (NK) cell activation. We investigated whether Coumarin inhibits liver cancer progression by enhancing NK cell effector functions, providing novel strategies for immunotherapy. MATERIALS AND
methodIn vitro, Sophora tonkinensis extract were screened in NK-92 cells. Cytokines (e.g., IFN-γ) were measured by ELISA; granzyme B and perforin levels were assessed via western blot and qPCR. Flow cytometry analyzed surface receptors. Findings were verified in primary human NK cells. In vivo, an H22 hepatocellular carcinoma syngeneic mouse model evaluated tumor growth. Immune cell infiltration in spleen and tumor tissues was quantified by flow cytometry and qPCR. Transcriptome sequencing and Seahorse metabolic analysis explored underlying mechanisms.
resultCoumarin significantly promoted NK cell activation. Synergizing with IL-12, it upregulated IFN-γ, granzyme B, and perforin transcription and enhanced their secretion and protein expression in both NK-92 and primary human NK cells. In vivo, Coumarin effectively inhibited H22 tumor growth, significantly reducing tumor volume. Flow cytometry revealed increased infiltration of NK cells and CD8⁺ T cells in tumor and spleen tissues. Transcriptomic analysis identified 194 upregulated and 67 downregulated genes, enriched in energy metabolism pathways. Seahorse analysis revealed that Cu significantly increased oxygen consumption rate (OCR), suggesting its ability to effectively restore energy supply in NK cells.
conclusionCu potentiates IL‑12-induced NK cell activation, accompanied by increased IFN-γ secretion and upregulated granzyme B and perforin expression. Cu inhibits hepatocellular carcinoma growth by improving NK cell cytotoxic function, remodeling the tumor immune microenvironment, and enhancing mitochondrial bioenergetic activity in NK cells. The present study preliminarily reveals the immunological and metabolic phenotypic mechanisms underlying the anti-tumor activity of coumarin. Notably, the current data only demonstrate elevated mitochondrial respiratory capacity without confirming comprehensive metabolic reprogramming or the direct molecular targets of coumarin. Collectively, these findings support that coumarin serves as a promising preclinical natural product candidate for liver cancer immunotherapy.
Indexed as
Identifiers
42837059What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.